2-(4-carboxyphenoxy)-5-[3-(4-octadecoxyphenyl)propanoylamino]benzoic Acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-carboxyphenoxy)-5-[3-(4-octadecoxyphenyl)propanoylamino]benzoic Acid
• 化学式: C₄₁H₅₅NO₇
• 分子量: 673.9
• InChiKey: KQPYKGFXDNTUMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  12.4
• 重原子数：
  49
• 可旋转键数：
  26
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.49
• 拓扑面积：
  122
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• [EN] Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R)<br/>[FR] UREE-OCTAHYDROINDOLES SUBSTITUES UTILISES EN TANT QU'ANTAGONISTES DU RECEPTEUR 1 DE L'HORMONE CONCENTRANT LA MELANINE (MCH1R)
  申请人：BIOVITRUM AB

  公开号：WO2005051381A1

  公开（公告）日：2005-06-09

  The invention relates to compounds of the general formula (I) wherein R0, R1, R2, R3, R4, R5, R6, R7, R8, R9, Ar, and X are as defined in the description, or a pharmaceutically acceptable salt, hydrates, geometrical isomers, racemates, tautomers, optical isomers, N-oxides and prodrug forms thereof. The compounds may be used for the treatment or prophylaxis of disorders related to the MCH1R receptor and for modulation of appetite. The invention also relates to such use as well as to pharmaceutical formulations comprising a compound of formula (I).

  该发明涉及通式（I）的化合物，其中R0、R1、R2、R3、R4、R5、R6、R7、R8、R9、Ar和X如描述中所定义，或其药学上可接受的盐、水合物、几何异构体、消旋体、互变异构体、光学异构体、N-氧化物及其前药形式。这些化合物可用于治疗或预防与MCH1R受体相关的疾病，并用于调节食欲。该发明还涉及该用途以及包含通式（I）化合物的药物配方。
• CARBOXYLIC ACID DERIVATIVE
  申请人：TAISHO PHARMACEUTICAL CO., LTD

  公开号：EP1466891A1

  公开（公告）日：2004-10-13

  The following compounds useful as VEGF receptor antagonists and having excellent physical properties are provided. A carboxylic acid derivative represented by formula: wherein ring A represents a benzene ring, a naphthalene ring, or the like; W represents a C1-5 alkylene group; Z represents a single bond or a phenylene group; R1 and R2 are the same or different and each represents a hydrogen atom, a halogen atom, a C1-5 alkyl group or a C1-10 alkoxy group; R3 represents a hydrogen atom, a halogen atom, a C1-12 alkyl group, a C2-5 alkynyl group, a trifluoromethyl group, an acetynyl group, a cyano group, a nitro group, -CH2-R6, -Y-R11, or the like; R4 represents a group represented by formula: and R5 represents a hydrogen atom or a C1-5 alkyl group, or a pharmaceutical acceptable salt of the derivative.

  提供以下化合物作为VEGF受体拮抗剂，具有优异的物理特性。一种由以下公式表示的羧酸衍生物：其中环A表示苯环、萘环或类似物；W表示C1-5烷基；Z表示单键或苯基；R1和R2相同或不同，分别表示氢原子、卤素原子、C1-5烷基或C1-10烷氧基；R3表示氢原子、卤素原子、C1-12烷基、C2-5炔基、三氟甲基、乙炔基、氰基、硝基、-CH2-R6、-Y-R11或类似物；R4表示以下公式表示的基团：和R5表示氢原子或C1-5烷基，或其药用可接受盐。
• Carboxylic acid derivative
  申请人：Saito Shuji

  公开号：US20050222423A1

  公开（公告）日：2005-10-06

  The following compounds useful as VEGF receptor antagonists and having excellent physical properties are provided. A carboxylic acid derivative represented by formula: wherein ring A represents a benzene ring, a naphthalene ring, or the like; W represents a C 1-5 alkylene group; Z represents a single bond or a phenylene group; R 1 and R 2 are the same or different and each represents a hydrogen atom, a halogen atom, a C 1-5 alkyl group or a C 1-10 alkoxy group; R 3 represents a hydrogen atom, a halogen atom, a C 1-12 alkyl group, a C 2-5 alkynyl group, a trifluoromethyl group, an acetylenyl group, a cyano group, a nitro group, —CH 2 —R 6 , —Y—R 11 , or the like; R 4 represents a group represented by formula: and R 5 represents a hydrogen atom or a C 1-5 alkyl group, or a pharmaceutical acceptable salt of the derivative.

  提供了以下化合物作为VEGF受体拮抗剂，并具有优异的物理性质。该化合物为羧酸衍生物，其表示为以下式子： 其中，环A代表苯环，萘环等；W代表C1-5烷基；Z代表单键或苯基；R1和R2相同或不同，分别代表氢原子，卤素原子，C1-5烷基或C1-10烷氧基；R3代表氢原子，卤素原子，C1-12烷基，C2-5炔基，三氟甲基，乙炔基，氰基，硝基，-CH2-R6，-Y-R11等；R4代表以下式子所表示的基团： R5代表氢原子或C1-5烷基，或其药用盐。
• SPECIFIC INHIBITORS FOR VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS
  申请人：Nova Southeastern University

  公开号：EP2271341B1

  公开（公告）日：2016-08-17
• VASCULAR ENDOTHELIAL RECEPTOR SPECIFIC INHIBITORS
  申请人：Rathinavelu Appu

  公开号：US20070249575A1

  公开（公告）日：2007-10-25

  The present application describes isoindoles and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful inhibitors of VEGFR.